Hold Rating for Longboard Pharmaceuticals Amidst Acquisition Uncertainty and Speculative Risks
Truist Financial Maintains Longboard Pharmaceuticals(LBPH.US) With Hold Rating
Truist Financial Upgrades Longboard Pharmaceuticals(LBPH.US) to Buy Rating, Maintains Target Price $60
H.C. Wainwright Maintains Longboard Pharmaceuticals(LBPH.US) With Buy Rating, Cuts Target Price to $60
Strong Valuation and Strategic Acquisition Drive Buy Rating for Longboard Pharmaceuticals
Longboard Pharmaceuticals Price Target Maintained With a $60.00/Share by Truist Securities
Longboard Pharmaceuticals Downgraded to Neutral From Buy at B. Riley
A Quick Look at Today's Ratings for Longboard Pharmaceuticals(LBPH.US), With a Forecast Between $60 to $60
Baird Downgrades Longboard Pharmaceuticals to Neutral From Outperform, Price Target Is $60
Longboard Pharmaceuticals Analyst Ratings
Longboard Pharmaceuticals Downgraded to Neutral From Buy at B. Riley
H.C. Wainwright Maintains Longboard Pharmaceuticals(LBPH.US) With Buy Rating, Raises Target Price to $80
A Quick Look at Today's Ratings for Longboard Pharmaceuticals(LBPH.US), With a Forecast Between $44 to $80
Longboard Pharmaceuticals Is Maintained at Outperform by Wedbush
Wedbush Maintains Longboard Pharmaceuticals(LBPH.US) With Buy Rating, Raises Target Price to $44
Truist Financial Maintains Longboard Pharmaceuticals(LBPH.US) With Buy Rating
Cantor Fitzgerald Reiterates Overweight on Longboard Pharmaceuticals, Maintains $90 Price Target
Longboard Pharmaceuticals Analyst Ratings
Truist Financial Initiates Longboard Pharmaceuticals(LBPH.US) With Buy Rating, Announces Target Price $60
Baird Maintains Longboard Pharmaceuticals(LBPH.US) With Buy Rating, Maintains Target Price $60